Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ISS 1018 CpG Oligodeoxynucleotide · CPG-1018

Oligonucleotide · Immune activation, directed at Toll-like receptor 9 (TLR9) · developed by Valneva Austria GmbH

Phase 1 Most advanced trial (none active)

VALN Developer

1 Registered trials

What is ISS 1018 CpG Oligodeoxynucleotide?

CpG 1018 is a short synthetic unmethylated CpG oligodeoxynucleotide that signals through Toll-like receptor 9 to stimulate immune responses, inducing B cell immunoglobulin production and interferon and cytokine release by plasmacytoid dendritic cells. It is being studied in combination with VLA1601 in Zika virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CPG-1018, CpG 1018
Drug type: Oligonucleotide
Targets: Toll-like receptor 9 (TLR9)
Mechanism: Immune activation, directed at Toll-like receptor 9 (TLR9)
Pathways: interferon production, NK cell activation, T-helper 1 differentiation, antigen presentation
Therapy area: Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: 25DT549L0G

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06334393	Phase 1	Zika	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ZikaZika Virus Infection

Other drugs acting on TLR9

Cavrotolimod Phase 1/2

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1553 Phase 3 VLA1601 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind ISS 1018 CpG Oligodeoxynucleotide

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z